AIM: Anthracycline-induced cardiotoxicity is (partly) mediated by free radical overload. A randomized study was performed in breast cancer patients to investigate whether free radical scavenger super oxide dismutase (SOD) protects against anthracycline-induced cardiotoxicity as measured by changes in echo, electrocardiography and an array of biomarkers. METHOD AND RESULTS: Eighty female, chemotherapy-naïve breast cancer patients (median age 49, range 24-67 years) scheduled for four or five courses of adjuvant 3 weeklydoxorubicin plus cyclophosphamide (AC) chemotherapy, were randomly assigned to receive 80 mg PC-SOD (human recombinant SOD bound to lecithin) or placebo, administered intravenously (i.v.) immediately prior to each AC course. The primary end point was protection against cardiac damage evaluated using echocardiography, QT assessments and a set of biochemical markers for myocardial function, oxidative stress and inflammation. Assessments were performed before and during each course of chemotherapy, and at 1, 4 and 9 months after completion of the chemotherapy regimen. In all patients cardiac effects such as increases in NT-proBNP concentration and prolongation of the QTc interval were noticed. There were no differences between the PC-SOD and placebo-treated patients in systolic or diastolic cardiac function or for any other of the biomarkers used to assess the cardiac effects of anthracyclines. CONCLUSION: PC-SOD at a dose of 80 mg i.v. is not cardioprotective in patients with breast carcinoma treated withanthracyclines.
RCT Entities:
AIM: Anthracycline-induced cardiotoxicity is (partly) mediated by free radical overload. A randomized study was performed in breast cancerpatients to investigate whether free radical scavenger super oxide dismutase (SOD) protects against anthracycline-induced cardiotoxicity as measured by changes in echo, electrocardiography and an array of biomarkers. METHOD AND RESULTS: Eighty female, chemotherapy-naïve breast cancerpatients (median age 49, range 24-67 years) scheduled for four or five courses of adjuvant 3 weekly doxorubicin plus cyclophosphamide (AC) chemotherapy, were randomly assigned to receive 80 mg PC-SOD (human recombinant SOD bound to lecithin) or placebo, administered intravenously (i.v.) immediately prior to each AC course. The primary end point was protection against cardiac damage evaluated using echocardiography, QT assessments and a set of biochemical markers for myocardial function, oxidative stress and inflammation. Assessments were performed before and during each course of chemotherapy, and at 1, 4 and 9 months after completion of the chemotherapy regimen. In all patients cardiac effects such as increases in NT-proBNP concentration and prolongation of the QTc interval were noticed. There were no differences between the PC-SOD and placebo-treated patients in systolic or diastolic cardiac function or for any other of the biomarkers used to assess the cardiac effects of anthracyclines. CONCLUSION: PC-SOD at a dose of 80 mg i.v. is not cardioprotective in patients with breast carcinoma treated with anthracyclines.
Authors: M T Meinardi; D J van Veldhuisen; J A Gietema; W V Dolsma; F Boomsma; M P van den Berg; C Volkers; J Haaksma; E G de Vries; D T Sleijfer; W T van der Graaf Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: D Cardinale; M T Sandri; A Martinoni; A Tricca; M Civelli; G Lamantia; S Cinieri; G Martinelli; C M Cipolla; C Fiorentini Journal: J Am Coll Cardiol Date: 2000-08 Impact factor: 24.094
Authors: Ken Nakagawa; Dicken D H Koo; David R Davies; Derek W R Gray; Andrew J McLaren; Kenneth I Welsh; Peter J Morris; Susan V Fuggle Journal: Kidney Int Date: 2002-03 Impact factor: 10.612
Authors: T Nousiainen; E Vanninen; E Jantunen; J Puustinen; J Remes; A Rantala; O Vuolteenaho; J Hartikainen Journal: J Intern Med Date: 2002-03 Impact factor: 8.989
Authors: M Hangaishi; H Nakajima; J Taguchi ; R Igarashi; J Hoshino; K Kurokawa; S Kimura; R Nagai; M Ohno Journal: Biochem Biophys Res Commun Date: 2001-08-03 Impact factor: 3.575
Authors: H Nakajima; M Hangaishi; N Ishizaka; J Taguchi; R Igarashi; Y Mizushima; R Nagai; M Ohno Journal: Life Sci Date: 2001-07-13 Impact factor: 5.037
Authors: H Nakajima; N Ishizaka; M Hangaishi; J Taguchi; J Itoh; R Igarashi; Y Mizushima; R Nagai; M Ohno Journal: Free Radic Biol Med Date: 2000-07-01 Impact factor: 7.376
Authors: Julian Puppe; Deborah van Ooyen; Jeanne Neise; Fabinshy Thangarajah; Christian Eichler; Stefan Krämer; Roman Pfister; Peter Mallmann; Marina Wirtz; Guido Michels Journal: Breast Care (Basel) Date: 2017-01-18 Impact factor: 2.860
Authors: Paola Rizzo; Donato Mele; Cristiana Caliceti; Micaela Pannella; Cinzia Fortini; Anthony George Clementz; Marco Bruno Morelli; Giorgio Aquila; Pietro Ameri; Roberto Ferrari Journal: Front Oncol Date: 2015-01-13 Impact factor: 6.244